HLB Co., Ltd.
028300
주식 순위
#4130
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
주가
$31.27
시가총액
$4.16B
변동 (1일)
6.78%
변동 (1년)
1.26%
국가
KR
거래 HLB Co., Ltd. (028300)
카테고리
Healthcare
HLB Co., Ltd. (028300)의 매출
Jun 2026 기준 매출 TTM: $67.40M
HLB Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $67.40M입니다. 2023년에 회사는 $33.14M의 수익을 올렸으며 이는 2022년의 $142.41M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
HLB Co., Ltd.의 수익 기록 (2012 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $67.40M | 45.45% |
| 2024 | $46.34M | 39.83% |
| 2023 | $33.14M | -76.73% |
| 2022 | $142.41M | 142.47% |
| 2021 | $58.73M | 13.50% |
| 2020 | $51.75M | 55.52% |
| 2019 | $33.27M | 2.38% |
| 2018 | $32.50M | 50.54% |
| 2017 | $21.59M | -13.64% |
| 2016 | $25.00M | -23.62% |
| 2015 | $32.73M | -3.69% |
| 2014 | $33.98M | 71.94% |
| 2013 | $19.76M | -59.26% |
| 2012 | $48.51M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 18,631.01% |
US
|
|
| $2.23B | 3,205.74% |
US
|
|
| $15.74B | 23,260.28% |
AU
|
|
| $6.02B | 8,833.94% |
NL
|
|
| - | - |
CH
|
